HealthInsu™ — The Model
A prevention subscription, with an insurance benefit attached.
Consumers subscribe to disease-prevention products on a regular cadence. If a covered condition occurs, they get an insurance payout. From their seat, they take care of their health day to day, and they have a safety net for what already happened if it does.
Why this model holds up
Three groups win at the same time.
That is what keeps it running.
Health plus a safety net
They subscribe because they want to look after their health — and because the insurance benefit riding along with it is worth something on its own.
Revenue that keeps coming back
Subscription consumption is not one-and-done shelf turnover — it is recurring revenue that shows up every cycle, and category loyalty compounds on top of it.
A new short-term group line
A new short-term group line priced on real cohort data — small per-cycle premiums, volume you can forecast, and a tighter loss ratio than anything broad-population underwriting can hand you.
How the insurer earns
A new short-term group line.
Priced on data, not on a guess.
The insurer side of HealthInsu™ is not a long-tail life or critical-illness book. It is a recurring short-term group structure sized to the subscription cohort and priced on what that cohort is actually doing.
Group short-term contracts
Benefits are issued as group short-term contracts. Each subscription cycle generates one small premium. Volume scales with the subscription base — predictable, recurring, and cleanly separated from long-tail life or critical-illness liabilities sitting on the insurer's book.
Priced on what the cohort actually does
Subscribers come in with a pre-enrollment baseline (intake exam, biomarkers) and keep an ongoing usage record. Insurers underwrite against the cohort's own data instead of broad-population tables — adverse selection drops, and the loss ratio tightens through the first 12 months of operation.
Bundled into the subscription, so acquisition cost lands at zero
The insurer reaches the insured pool through the manufacturer's existing subscription channel. No separate marketing spend, no broker stack to feed. The benefit ships as part of the product — it is not a standalone policy anyone has to go sell.
A clean handoff into traditional lines
Subscribers who finish a year of the structured prevention routine — or who experience a benefit payout — have a real reason to look at the insurer's traditional health, cancer, or critical-illness lines. The HealthInsu™ cohort becomes a warm top-of-funnel for the rest of the book.
The actual policy structure (term length, scope of cover, premium split, reinsurance treatment) is defined per country and per partner insurer under separate agreement. HealthInsu™ supplies the framework; local regulation decides the contract form.
How it works in practice
A six-step playbook, run end-to-end by your country team.
Select & validate
Pick a disease-specific prevention product and pressure-test it against your local market and regulation.
Wire in clinical
Connect the product to physicians, exams, and check-up systems on the ground.
Subscribe
Consumers subscribe — monthly, or through a structured trial program.
Confirm results
Results get confirmed through tests, biomarkers, and follow-up exams.
Link to insurance
Tie the product to an insurance benefit to build trust and take the friction out of the buying decision.
Compound the trust
Every loop the validated product runs, it puts more distance between itself and legacy brand-driven products on the shelf.
The patent layer
Protected at the structure, not just at the product.
Prevention plus insurance, structured
The subscription-to-benefit linkage between preventive products and insurance is locked down as a business-model patent — not as a single product claim.
Validation and verification systems
The validation flow (clinic, exam, biomarker, follow-up) sits behind a system patent, layered on top of the business-model claim.
Patent protection is built in layers — typically two to four — so the model holds across jurisdictions and product categories. Country-level licensing terms are defined under separate agreement.
Not a guarantee — a structured risk-sharing program
The framing matters.
HealthInsu™ is not a "we guarantee prevention" license. It is a B2B framework that closes the verification gap consumers feel in the prevention category — through 1-year usage data, conditional compensation structures, and operating standards co-defined with each licensee.
Less hesitation, better retention
The risk-sharing layer takes friction out of higher-ticket and subscription purchases, and ties continued use to the benefit structure so 12-month retention holds up.
Verified use, not promises
What they see is a transparent 1-year structure with defined check-in points — not marketing claims about cure or guaranteed prevention.
Pilot first, then scale
We usually start with one product and one customer cohort — a 100-person pilot (then 300, then 1,000) over a 12-month observation window. The pilot is not there to confirm medical efficacy. It is there to measure purchase conversion, retention, satisfaction, repurchase rate, and compensation claim rate — and the pilot results inform the full license terms.